Next Article in Journal
Invariant Natural Killer T-Cells and Total CD1d Restricted Cells Differentially Influence Lipid Metabolism and Atherosclerosis in Low Density Receptor Deficient Mice
Next Article in Special Issue
Hadrontherapy Interactions in Molecular and Cellular Biology
Previous Article in Journal
Enhancing the Thermo-Stability and Anti-Biofilm Activity of Alginate Lyase by Immobilization on Low Molecular Weight Chitosan Nanoparticles
Previous Article in Special Issue
Robustness of Clonogenic Assays as a Biomarker for Cancer Cell Radiosensitivity
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 20
Issue 18
10.3390/ijms20184563
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

FGFR Signaling as a Candidate Therapeutic Target for Cancers Resistant to Carbon Ion Radiotherapy

by
Narisa Dewi Maulany Darwis
1,†,
Ankita Nachankar
1,†,
Yasushi Sasaki
2,†,
Toshiaki Matsui
1,
Shin-ei Noda
1,
Kazutoshi Murata
1,
Tomoaki Tamaki
1,
Ken Ando
1,
Noriyuki Okonogi
1,
Shintaro Shiba
1,
Daisuke Irie
1,
Takuya Kaminuma
1,
Takuya Kumazawa
1,
Mai Anakura
1,
Souichi Yamashita
3,
Takashi Hirakawa
3,
Sangeeta Kakoti
1,
Yuka Hirota
1,
Takashi Tokino
2,
Akira Iwase
3,
Tatsuya Ohno
4,
Atsushi Shibata
5,
Takahiro Oike
1,4,* and
Takashi Nakano
1add Show full author list remove Hide full author list
1
Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan
2
Department of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University, Sapporo 060-8556, Japan
3
Department of Obstetrics and Gynecology, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan
4
Gunma University Heavy Ion Medical Center, Maebashi 371-8511, Japan
5
Gunma University Initiative for Advanced Research (GIAR), Maebashi 371-8511, Japan
*
Author to whom correspondence should be addressed.
†
These authors equally contributed to this work.
Int. J. Mol. Sci. 2019, 20(18), 4563; https://doi.org/10.3390/ijms20184563
Submission received: 22 August 2019 / Revised: 10 September 2019 / Accepted: 12 September 2019 / Published: 14 September 2019
(This article belongs to the Special Issue Counteracting Radioresistance Using the Optimization of Radiotherapy)
Browse Figures
Review Reports Versions Notes

Abstract

Radiotherapy is an essential component of cancer therapy. Carbon ion radiotherapy (CIRT) promises to improve outcomes compared with standard of care in many cancers. Nevertheless, clinicians often observe in-field recurrence after CIRT. This indicates the presence of a subset of cancers that harbor intrinsic resistance to CIRT. Thus, the development of methods to identify and sensitize CIRT-resistant cancers is needed. To address this issue, we analyzed a unique donor-matched pair of clinical specimens: a treatment-naïve tumor, and the tumor that recurred locally after CIRT in the same patient. Exon sequencing of 409 cancer-related genes identified enrichment of somatic mutations in FGFR3 and FGFR4 in the recurrent tumor compared with the treatment-naïve tumor, indicating a pivotal role for FGFR signaling in cancer cell survival through CIRT. Inhibition of FGFR using the clinically available pan-FGFR inhibitor LY2874455 sensitized multiple cancer cell lines to carbon ions at 3 Gy (RBE: relative biological effectiveness), the daily dose prescribed to the patient. The sensitizer enhancement ratio was 1.66 ± 0.17, 1.27 ± 0.09, and 1.20 ± 0.18 in A549, H1299, and H1703 cells, respectively. Our data indicate the potential usefulness of the analytical pipeline employed in this pilot study to identify targetable mutations associated with resistance to CIRT, and of LY21874455 as a sensitizer for CIRT-resistant cancers. The results warrant validation in larger cohorts.
Keywords: carbon ion radiotherapy; uterine cervical cancer; next-generation sequencer; somatic mutations; FGFR; radiosensitization; LY2874455 carbon ion radiotherapy; uterine cervical cancer; next-generation sequencer; somatic mutations; FGFR; radiosensitization; LY2874455

Share and Cite

MDPI and ACS Style

Darwis, N.D.M.; Nachankar, A.; Sasaki, Y.; Matsui, T.; Noda, S.-e.; Murata, K.; Tamaki, T.; Ando, K.; Okonogi, N.; Shiba, S.; et al. FGFR Signaling as a Candidate Therapeutic Target for Cancers Resistant to Carbon Ion Radiotherapy. Int. J. Mol. Sci. 2019, 20, 4563. https://doi.org/10.3390/ijms20184563

AMA Style

Darwis NDM, Nachankar A, Sasaki Y, Matsui T, Noda S-e, Murata K, Tamaki T, Ando K, Okonogi N, Shiba S, et al. FGFR Signaling as a Candidate Therapeutic Target for Cancers Resistant to Carbon Ion Radiotherapy. International Journal of Molecular Sciences. 2019; 20(18):4563. https://doi.org/10.3390/ijms20184563

Chicago/Turabian Style

Darwis, Narisa Dewi Maulany, Ankita Nachankar, Yasushi Sasaki, Toshiaki Matsui, Shin-ei Noda, Kazutoshi Murata, Tomoaki Tamaki, Ken Ando, Noriyuki Okonogi, Shintaro Shiba, and et al. 2019. "FGFR Signaling as a Candidate Therapeutic Target for Cancers Resistant to Carbon Ion Radiotherapy" International Journal of Molecular Sciences 20, no. 18: 4563. https://doi.org/10.3390/ijms20184563

APA Style

Darwis, N. D. M., Nachankar, A., Sasaki, Y., Matsui, T., Noda, S.-e., Murata, K., Tamaki, T., Ando, K., Okonogi, N., Shiba, S., Irie, D., Kaminuma, T., Kumazawa, T., Anakura, M., Yamashita, S., Hirakawa, T., Kakoti, S., Hirota, Y., Tokino, T., ... Nakano, T. (2019). FGFR Signaling as a Candidate Therapeutic Target for Cancers Resistant to Carbon Ion Radiotherapy. International Journal of Molecular Sciences, 20(18), 4563. https://doi.org/10.3390/ijms20184563

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop